Humacyte
HUMA
143 hedge funds and large institutions have $195M invested in Humacyte in 2024 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 54 increasing their positions, 25 reducing their positions, and 15 closing their positions.
133% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 15
116% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 25
30% more capital invested
Capital invested by funds: $150M → $195M (+$44.9M)
16% more funds holding
Funds holding: 123 → 143 (+20)
3.74% more ownership
Funds ownership: 26.2% → 29.94% (+3.7%)
62% less call options, than puts
Call options by funds: $2.01M | Put options by funds: $5.27M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$12.5M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$5.59M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$3.78M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.59M |
| 5 |
BlackRock
New York
|
+$2.63M |
Top Sellers
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.59M |
| 2 |
Renaissance Technologies
New York
|
-$2.88M |
| 3 |
D.E. Shaw & Co
New York
|
-$2.82M |
| 4 |
Millennium Management
New York
|
-$2.19M |
| 5 |
DM
Deerfield Management
New York
|
-$1.55M |
HUMA Hedge Fund Activity: Q3 2024 in Review
143 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q3 2024, worth a combined $195M — up 30% from $150M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new HUMA positions and 15 closed out — a net gain of 20 holders — while 54 added to existing stakes and 25 trimmed.
The largest buyer was State Street, adding an estimated $12.5M. The largest seller was Nuveen, cutting an estimated $5.59M.
- 143 institutional investors held Humacyte (HUMA) as of Q3 2024, up from 123 in Q2 2024.
- Funds reported $195M of Humacyte stock for Q3 2024, up 30% quarter-over-quarter.
- 35 funds opened new Humacyte positions in Q3 2024 and 15 closed out, a net change of +20 holders.
- The largest Humacyte buyer in Q3 2024 was State Street, an estimated $12.5M added.
- The largest Humacyte seller in Q3 2024 was Nuveen, an estimated $5.59M sold.
Based on aggregated 13F filings for Q3 2024.